ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Association between the use of lipid-lowering drugs and the risk of inflammatory bowel disease

Liu, Xuxu; Lv, Zhenyi; Xie, Zhihong; Wang, Qiang; Yao, Wenchao; Yu, Jingjing; Jing, Qingxu; Meng, Xianzhi; Ma, Biao; Xue, Dongbo*; Hao, Chenjun*哈尔滨医科大学; 1
European Journal of Clinical Investigation2023-12DOI: 10.1111/eci.14067
1被引11阅读
引用收藏
分享

摘要

Background: Observational studies have suggested an association between lipid-lowering drugs and inflammatory bowel disease (IBD) risk. This study aimed to assess the causal influence of lipid-lowering agents on IBD risk using Mendelian randomization analysis. @@@ Method: In a population of 173,082 individuals of European ancestry, 55 single-nucleotide polymorphisms were identified as instrumental variables for 6 lipid-lowering drug targets (HMGCR, NPC1LC, PCSK9, LDLR, CETP and APOB). Summary statistics for the genome-wide association study of IBD, ulcerative colitis (UC) and Crohn's disease (CD) were obtained from the FinnGen consortium, Program in Complex Trait Genomics and UK Biobank. Inverse-variance weighted was employed as the primary MR method, and odds ratios (ORs) with 95% confidence intervals were reported as the results. Sensitivity analyses using conventional MR methods were conducted to assess result robustness. @@@ Results: Gene-proxied inhibition of Niemann-Pick C1-like 1 (NPC1L1) was associated with an increased IBD risk (OR [95% CI]: 2.31 [1.38, 3.85]; p = .001), particularly in UC (OR [95% CI]: 2.40 [1.21, 4.74], p = .012), but not in CD. This finding was replicated in the validation cohort. Additionally, gene-proxied inhibition of low-density lipoprotein receptor was associated with reduced IBD (OR [95% CI]:.72 [.60,.87], p < .001) and UC risk (OR [95% CI]:.74 [.59,.92], p = .006), although this result was not replicated in the validation cohort. Other drug targets did not show significant associations with IBD, UC or CD risk. @@@ Conclusion: Inhibition of the lipid-lowering drug-target NPC1L1 leads to an increased IBD risk, mainly in the UC population.

学科与关键词

关键词
inflammatory bowel diseaselipid-lowering drugMendelian randomization
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Clinical Investigation
发表日期
2023-12
卷期
第 53 卷, 第 12 期
页码
e14067
DOI
10.1111/eci.14067
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82170654, 82100675]; Key Research and Development Program of Heilongjiang Province [2022ZX06C06]; Excellent Youth Foundation of the First Affiliated Hospital of Harbin Medical University [2021Y12]

作者

  • L

    Liu, Xuxu (第一作者)

    1 · harbin med univ

  • L

    Lv, Zhenyi

    1 · harbin med univ

查看全部 11 位作者收起作者
  • X

    Xie, Zhihong

    1 · harbin med univ

  • W

    Wang, Qiang

    1 · harbin med univ

  • Y

    Yao, Wenchao

    1 · harbin med univ

  • Y

    Yu, Jingjing

    1 · harbin med univ

  • J

    Jing, Qingxu

    1 · harbin med univ

  • M

    Meng, Xianzhi

    1 · harbin med univ

  • M

    Ma, Biao

    1 · harbin med univ

  • X

    Xue, Dongbo (通讯)

    1 · harbin med univ

  • H

    Hao, Chenjun (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417